YS Biopharma Co (YS Biopharma Co) EV-to-FCF : -5.92 (As of May. 16, 2024)

View and export this data going back to 2023. Start your Free Trial

What is YS Biopharma Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, YS Biopharma Co's Enterprise Value is $234.66 Mil. YS Biopharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 was $-39.63 Mil. Therefore, YS Biopharma Co's EV-to-FCF for today is -5.92.

The historical rank and industry rank for YS Biopharma Co's EV-to-FCF or its related term are showing as below:

YS' s EV-to-FCF Range Over the Past 10 Years
Min: -12.78 Med: -2.79 Max: -1.53
Current: -5.92

During the past 3 years, the highest EV-to-FCF of YS Biopharma Co was -1.53. The lowest was -12.78. And the median was -2.79.

YS's EV-to-FCF is ranked worse than
100% of 381 companies
in the Biotechnology industry
Industry Median: 7.56 vs YS: -5.92

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-16), YS Biopharma Co's stock price is $0.950101. YS Biopharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.569. Therefore, YS Biopharma Co's PE Ratio for today is At Loss.

YS Biopharma Co EV-to-FCF Historical Data

The historical data trend for YS Biopharma Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

YS Biopharma Co EV-to-FCF Chart

YS Biopharma Co Annual Data

Trend

Mar21

Mar22

Mar23

EV-to-FCF

-4.82

YS Biopharma Co Semi-Annual Data
	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EV-to-FCF	Get a 7-Day Free Trial			-	-	-	-4.82	-

Competitive Comparison of YS Biopharma Co's EV-to-FCF

For the Biotechnology subindustry, YS Biopharma Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

YS Biopharma Co's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, YS Biopharma Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where YS Biopharma Co's EV-to-FCF falls into.

YS Biopharma Co EV-to-FCF Calculation

YS Biopharma Co's EV-to-FCF for today is calculated as:

EV-to-FCF	=	Enterprise Value (Today)	/	Free Cash Flow (TTM)
	=	234.658	/	-39.627
	=	-5.92

YS Biopharma Co's current Enterprise Value is $234.66 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. YS Biopharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 was $-39.63 Mil.

YS Biopharma Co (NAS:YS) EV-to-FCF Explanation

YS Biopharma Co's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.950101	/	-0.569
	=	At Loss

YS Biopharma Co's share price for today is $0.950101.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. YS Biopharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.569.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

YS Biopharma Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of YS Biopharma Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

YS Biopharma Co (YS Biopharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » YS Biopharma Co Ltd (NAS:YS) » Definitions » EV-to-FCF

Comparable Companies

Traded in Other Exchanges

H6Z:Germany

Address

38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629

Website

https://www.yishengbio.com

YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.